Romanian market continued to grow at double-figure rate in Q1 2019

…used for central nervous system disorders grew by 6% only. The order of the 3 leading corporations in terms of value has changed in Q1 2019 in the wake of the significant growth in medicines allocated to cost-volume-result contracts (for interferon free therapy for hepatitis C).

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.